Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure

NCT03030235 is registered in ClinicalTrials.gov with Saint Luke's Health System as lead sponsor.

NCT NCT03030235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03030235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients With PRESERVED Ejection Fraction Heart Failure
Lead sponsor
Saint Luke's Health System
Phase
Phase 4
Overall status
Completed
Start date
March 1, 2017
Completion date
August 13, 2021
Enrollment
324 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure with preserved systolic function